Showing results (941-950 of 1,110) with videos related to

Sort By:
Pageof 111
Prenatal Diagnosis|March 3, 2018
Growth patterns in fetuses with isolated cardiac defectsIlse Haveman, Johanna H Fleurke-Rozema, Eduard J H Mulder, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1985
High-dose cyclophosphamide and high-dose VP 16-213 for recurrent or refractory small cell lung cancer. A phase II studyP E Postmus, N H Mulder, H G de Vries-Hospers, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 11, 2010
FDG-PET probe-guided surgery for recurrent retroperitoneal testicular tumor recurrencesJ S de Jong, R J van Ginkel, R H J A Slart, et al.
Anti-Cancer Drugs|June 19, 2004
Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrationsArthur R Van Gool, Heidi H van Ojik, Wim H J Kruit, et al.
Breast Cancer Research and Treatment|January 1, 1996
Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancerE G de Vries, S Rodenhuis, H C Schouten, et al.
European Journal of Nuclear Medicine|June 1, 1994
Somatostatin analogue scintigraphy in granulomatous diseasesP M Vanhagen, E P Krenning, J C Reubi, et al.
Development and Psychopathology|April 13, 2017
Methylation matters: FK506 binding protein 51 (FKBP5) methylation moderates the associations of FKBP5 genotype and resistant attachment with stress regulationRosa H Mulder, Jolien Rijlaarsdam, Maartje P C M Luijk, et al.
British Journal of Cancer|January 1, 1997
A new in vitro assay for quantitation of chemotherapy-induced mucositisA N Wymenga, W T van der Graaf, F L Spijkervet, et al.
Oncology|January 1, 1983
Influence of combination chemotherapy with cis-diamminedichloroplatinum on renal function: long-term effectsS Meijer, N H Mulder, D T Sleijfer, et al.
British Journal of Cancer|February 1, 1993
A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 daysJ A Gietema, E G de Vries, D T Sleijfer, et al.
Pageof 111